I assume that this is a question about IL-1? In which case I'd suggest a board search since this has been discussed previously:
a) Several different competitor IL-1 agonists in work. XOMAs is a little more targetted than most of the others (which might be good or bad depending upon the efficacy vs safety issues that crop up on IL-1 treatments).
b) XOMA appears to be targetting interesting indications not being pursued by competitors (e.g. diabetes), althought no inherent reason that other IL-1 agnoists wouldn't work as well.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.